Healthcare
Fisher & Paykel Healthcare Corporation Limited(FSPKF)
Live Price
Offline$22.52
+0.00% today
1Y Change
+8.79%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $21.00B
- Revenue Growth
- -27.2%
- EPS Growth
- +178.3%
- Dividend Yield
- 1.2%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fisher & Paykel Healthcare Corporation Limited (FSPKF) is a Healthcare stock with a market cap of $21.00B and listed on OTC. The stock last traded around $22.52 and up 8.8% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -27.2%, EPS growth of +178.3%, a dividend yield of 1.2%. What stands out right now is revenue -27.2%, EPS +178.3%, free cash flow +391.8% with operating margin 27.2% and ROIC 19.0%. The dividend is present but secondary, with a yield around 1.2%. Valuation already assumes a fairly strong business story at P/E 49.9 and price/sales 10.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines FSPKF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-27.2% vs +7.6% peer median
Operating Margin
Above sector median
+27.2% vs +19.4% peer median
P/E
Above sector median
49.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 28, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -27.2% and EPS is at +178.3%, with operating margin around 27.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 28, 2026 | โ | +0.0% | +0.0% | โ |
2025 Nov 25, 2025 | +5.2% | +0.0% | +0.0% | -6.3% |
2025 May 27, 2025 | +75.1% | +0.0% | +6.8% | -3.3% |
Benchmark Edge
FSPKF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FSPKF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FSPKF Max Drawdown
-17.80%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FSPKF and SPY.
Company Overview
Fisher & Paykel Healthcare Corporation Limited
Other OTC
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system. In addition, it provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
- Leadership
- Lewis G. Gradon
- IPO Date
- Jul 11, 2001
- Employees
- 7.0k
- Street Address
- 15 Maurice Paykel Place
- Mailing
- Auckland, 2013
- Region
- Auckland, NZ
- Reporting Currency
- USD
- Investor Line
- 64 9 574 0100
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 49.9
- EV/EBITDA
- 30.4
- Price/Sales
- 10.0
- Price/Book
- 10.6
Growth
- Revenue
- -27.2%
- EPS
- +178.3%
- Free Cash Flow
- +391.8%
Profitability
- Gross Margin
- 63.6%
- Operating Margin
- 27.2%
- Net Margin
- 20.1%
- ROE
- 22.5%
- ROIC
- 19.0%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 2.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.